Helsinn Group

Last days of #BreastCancerAwarenessMonth. Effectively managing nausea and vomiting (NV) related to anticancer treatments with certain antibody–drug conjugates (ADCs) is critical to enhance patients’ quality of life and ensure optimal adherence to treatments. International guidelines recommend the use of a tailored antiemetic prophylaxis to prevent NV in patients receiving the ADCs trastuzumab deruxtecan and sacituzumab govitecan. #BreastCancer #SupportiveCare #seecinvbetter

Celebrating work anniversaries at Helsinn Healthcare! 🏆🎉 Several colleagues at our headquarters in Lugano reach important anniversaries this year: - Annalisa Sonzogni – Finance – 30 years - Alberto Antonini – Finance – 25 years - Luis Vieira – Business Development – 20 years - Rino Durini – International Commercial Business – 20 years - Luisa Maino – Pharmacovigilance – 20 years - Tulla Spinelli – Clinical Affairs – 20 years - Valentina Tombolini Bossi – Medical Strategy and Excellence – 20 years Congratulations and thank you all for your invaluable contributions! Wishing you many more years of success and collaboration! 💯 #Helsinn #Careers #WorkAnniversary

We are excited to announce the launch of our new Helsinn Therapeutics (U.S.), Inc. LinkedIn page! Follow it to stay up to date with the latest news and achievements!

Fourth week of #BreastCancerAwarenessMonth! Nausea and vomiting (NV) are common side effects of anticancer treatments, typically assessed in the acute (first 24 hours) and delayed (days 2-5) phases post-treatment. Increasing focus is now on NV persisting beyond day 5 (long-delayed phase), highlighted by emerging data on certain antibody-drug conjugates (ADCs) suggesting that NV may continue well into the long-delayed phase for some patients. Preserving patients’ quality of life and ensuring uninterrupted treatment are vital for optimizing outcomes and maximizing treatment effectiveness. #BreastCancer #SupportiveCare #seecinvbetter

Join us at #BIOEurope in a few weeks! Luis Vieira and Lucia Stella Cafagna will be in Stockholm from 4-6 November, ready to explore potential new collaborations. Connect with them and discover what makes Helsinn a partner of choice. Feel free to visit our website for more information: https://lnkd.in/dkvGr7y5 Looking forward to seeing you there! #Helsinn #Partnering #Licensing

#BreastCancerAwarenessMonth continues. Evolving data on new antibody-drug conjugates (ADCs) suggest that some may cause nausea and vomiting lasting more than 5 days (referred to as “long-delayed CINV”). Administering guideline-recommended antiemetic prophylaxis is critical, especially considering the extended treatment duration for many patients. As uncontrolled CINV significantly increases the risk for CINV in subsequent cycles, appropriate upfront antiemetics when initiating ADCs are essential to optimize patient outcomes. #BreastCancer #SupportiveCare #seecinvbetter

Professor Emmanuella Guenova shares her considerations on the importance of tumour microenvironment in the evolution of MF-CTCL (mycosis-fungoides cutaneous T-cell lymphoma). Watch the video to learn more. 👇   #EORTC2024 #CTCL #Helsinn

Here is our team attending the EORTC CLTG 2024 Annual Meeting in Lausanne. This is an important venue to present new research, facilitate the exchange of experiences and allow discussion on the advancement of knowledge in cutaneous lymphoma tumour group. Don't miss the opportunity to get in touch with them! Alessandra Cogliati PharmD | Silvia Olivari Tilola | Valeriia Zinoveva #EORTC2024 #CTCL #Helsinn

Silvia Olivari Tilola, Head of Medical Strategy and Excellence, reflects on the work we are doing to support the Mycosis Fungoides Cutaneous T-Cell Lymphoma (MF-CTCL) community. #EORTC2024 #CTCL #Helsinn

📌 Helsinn is pleased to attend the EORTC CLTG Annual Meeting, taking place from 9 to 11 October in Lausanne, Switzerland. During the conference, we will be supporting the symposium entitled “Early-stage MF-CTCL and disease progression - what drives progression and how do we tackle it?” Professor Adèle de Masson and Gabor Dobos MD PhD will describe the role of tumour microenvironment in MF-CTCL. 👉 Learn more about Mycosis Fungoides Cutaneous T-Cell Lymphoma here: https://lnkd.in/dTd3Mh4x #EORTC2024 #CutaneousLymphoma #Helsinn